---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112053"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:04:47.029286+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunome acquires full ownership of ROR1 ADC assets from Zentalis for 1.8M shares plus $5M milestone

## Summary
- Issued 1,805,502 shares of common stock to Zentalis as partial consideration for the asset purchase.
- Obligated to pay $5M cash upon achievement of a developmental milestone; prior License Agreement terminated.
- Standstill restrictions on Zentalis for one year; lockup on selling >50% of shares for six months.
- Immunome to file resale registration statement within 30 days for shares issued to Zentalis.
- Asset purchase includes ROR1 antibody-drug conjugate platform and related intellectual property.

## SEC filing metadata
- accession: 0001104659-24-112053
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924112053/0001104659-24-112053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924112053/tm2426946d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112053
- JSON: https://secwatch.observer/filing/0001104659-24-112053.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112053.txt

## Key facts
- M&A Transactions
  Immunome Inc. completed an acquisition involving Zentalis Pharmaceuticals, Inc. for 1,805,502 shares of Company common stock (closed 2024-10-25).
  - Action: acquisition
  - Counterparty: Zentalis Pharmaceuticals, Inc.
  - Consideration: 1,805,502 shares of Company common stock
  - Closing: 2024-10-25
  source text: the customary rights and obligations of a sole owner (the “Asset Purchase”). Under the Purchase Agreement, in consideration of the Asset Purchase, the Company issued to Zentalis 1,805,502 shares of Company common stock (the “Shares”), described below under Stock Issuance Agreement . The Company is also obligated to pay Zentalis a one-time payment of $5,000,000 in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924112053/0001104659-24-112053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.